EU/3/19/2140: Orphan designation for the treatment of mucopolysaccharidosis type II (Hunter's syndrome)

Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase

Table of contents

Overview

On 26 February 2019, orphan designation (EU/3/19/2140) was granted by the European Commission to Artemida Pharma Europe Limited, Ireland, for humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase (also known as JR-141) for the treatment of mucopolysaccharidosis type II (Hunter’s syndrome).

Key facts

Active substance
Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase
Intended use
Treatment of mucopolysaccharidosis type II (Hunter's syndrome)
Orphan designation status
Positive
EU designation number
EU/3/19/2140
Date of designation
26/02/2019
Sponsor

Artemida Pharma Europe Limited
The Black Church
Saint Mary's Place North
Dublin 7 D07 P4AX
Ireland
Tel. +353 1437 2313
E-mail: artemida@artemidapharma.com

 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating